Approach A. Evidences favouring the prescription of selective COX-2 inhibitors;Aproximación A. Evidencias a favor de la prescripción de los inhibidores selectivos de la COX-2

Gastroenterologia y Hepatologia

Volumn 31, Issue SUPPL. 2, 2008, Pages 34-41

  Martín de Argila de Prados, Carlos ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; PARECOXIB; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ARTICLE; DIGESTIVE SYSTEM INJURY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TRACT; HUMAN; OSTEOARTHRITIS; PRESCRIPTION; RHEUMATOID ARTHRITIS; SPAIN; STOMACH BLOOD FLOW; STOMACH PROTECTION; VASODILATATION;

EID: 64949136541     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13126298     Document Type: Article

References (37)

1. Hawkey C.J. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 119 (2000) 521-535
2. Lanas A., Rodrigo L., Márquez J.L., Bajador E., Pérez-Roldan F., Cabrol J., et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 38 (2003) 693-700
3. Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 20 (2004) 321-331
4. Simmons D.L., Xie W., Chipman J.G., and Evett G.E. In: Bailey J.M. (Ed). Prostaglandins, Leukotrienes, Lipoxins and PAF (1991), Plenum, New York 67-78x
5. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
6. Sciulli M.G., Capone M.L., Tacconelli S., and Patrignani P. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 57 Suppl (2005) 66-85
7. Chen J.T., Pucino F., and Resman-Targoff B.H. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?. J Pain Palliat Care Pharmacother 20 (2006) 11-32
8. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
9. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. Engl J Med 343 (2000) 1520-1528
10. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
11. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
12. Singh G., Fort J.G., Goldstein J.L., Levy R.A., Hanrahan P.S., Bello A.E., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119 (2006) 255-266
13. Ramey D.R., Watson D.J., Yu C., Bolognese J.A., Curtis S.P., and Reicin A.S. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 21 (2005) 715-722
14. Hooper L., Brown T.J., Elliott R., Payne K., Roberts C., and Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329 (2004) 948-952
15. Lanas A., García-Rodríguez L.A., Arroyo M.T., Gomollón F., Feu F., González-Pérez A., et al. Risk of upper gastrointestinal ulcer bleeding associated with selectivecyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
16. Laine L., Connors L.G., Reicin A., Hawkey C.J., Burgos-Vargas R., Schnitzer T.J., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
17. Chan F.K., Hung L.C., Suen B.Y., Wu J.C., Lee K.C., Leung V.K., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
18. Goldstein J.L., Eisen G.M., Lewis B., Gralnek I.M., Zlotnick S., Fort J.G., et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3 (2005) 133-141
19. Chan F.K., Hung L.C., Suen B.Y., Wong V.W., Hui A.J., Wu J.C., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127 (2004) 1038-1043
20. Lai K.C., Chu K.M., Hui W.M., Wong B.C., Hu W.H., Wong W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
21. Scheiman J.M., Yeomans N.D., Talley N.J., Vakil N., Chan F.K., Tulassay Z., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
22. Chan F.K., Wong V.W., Suen B.Y., Wu J.C., Ching J.Y., Hung L.C., et al. Combination of a cyclo-oxygenase-2 inhibitor and a protonpump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626
23. Lanas A., and Ferrández A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 7 (2006) 127-133
24. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
25. Cairns J.A. The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks. Can J Cardiol 23 (2007) 125-131
26. Food and Drug Administration. Advisory committee briefing document: celecoxib and valdecoxib cardiovascular safety [citado Dic 2007]. Disponible en: www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex- Bextra.pdf
27. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1 (2006) 33
28. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
29. Caldwell B., Aldington S., Weatherall M., Shirtcliffe P., and Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99 (2006) 132-140
30. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
31. Furberg C.D., Psaty B.M., and FitzGerald G.A. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 111 (2005) 249
32. Hawkey C.J., Gitton X., Hoexter G., Richard D., and Weinstein W.M. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. Clin Gastroenterol Hepatol 4 (2006) 57-66
33. Curtis S.P., Bockow B., Fisher C., Olaleye J., Compton A., Ko A.T., et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT0 0242489]. BMC Musculoskelet Disord 6 (2005) 58
34. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330 (2005) 1366-1373
35. Sopena F., and Lanas A. How to advise aspirin use in patients who need NSAIDs. Curr Pharm Des 13 (2007) 2248-2260
36. Rostom A., Dubé C., Lewin G., Tsertsvadze A., Barrowman N., Code C., et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146 (2007) 376-389
37. Liao Z., Mason K.A., and Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?. Drugs 67 (2007) 821-845